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ARTICLE
Genetic and pharmacological inhibition of
microRNA-92a maintains podocyte cell cycle
quiescence and limits crescentic
glomerulonephritis
Carole Henique1,2,3,4, Guillaume Bollée1,2,5, Xavier Loyer1,2, Florian Grahammer6,7,8, Neeraj Dhaun1,9,
Marine Camus1, Julien Vernerey1, Léa Guyonnet1,2, François Gaillard1,2, Hélène Lazareth1,2, Charlotte Meyer8,
Imane Bensaada1,2, Luc Legrès10, Takashi Satoh11, Shizuo Akira11, Patrick Bruneval2,12,13, Stefanie Dimmeler14,
Alain Tedgui1,2, Alexandre Karras1,2,13,15, Eric Thervet1,2,13,15, Dominique Nochy2,12,13, Tobias B. Huber6,7,8,
Laurent Mesnard16,17, Olivia Lenoir1,2 & Pierre-Louis Tharaux 1,2,15
Crescentic rapidly progressive glomerulonephritis (RPGN) represents the most aggressive
form of acquired glomerular disease. While most therapeutic approaches involve potentially
toxic immunosuppressive strategies, the pathophysiology remains incompletely understood.
Podocytes are glomerular epithelial cells that are normally growth-arrested because of the
expression of cyclin-dependent kinase (CDK) inhibitors. An exception is in RPGN where
podocytes undergo a deregulation of their differentiated phenotype and proliferate. Here we
demonstrate that microRNA-92a (miR-92a) is enriched in podocytes of patients and mice
with RPGN. The CDK inhibitor p57Kip2 is a major target of miR-92a that constitutively
safeguards podocyte cell cycle quiescence. Podocyte-specific deletion of miR-92a in mice de-
repressed the expression of p57Kip2 and prevented glomerular injury in RPGN. Administration
of an anti-miR-92a after disease initiation prevented albuminuria and kidney failure, indicating
miR-92a inhibition as a potential therapeutic strategy for RPGN. We demonstrate that miRNA
induction in epithelial cells can break glomerular tolerance to immune injury.
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Necrotizing and crescentic rapidly progressive glomer-ulonephritis (RPGN) is one of the severest forms of glo-merular disease. RPGN can occur in the setting of a
number of immunological disorders including anti-glomerular
basement membrane (anti-GBM) disease, anti-neutrophil cyto-
plasmic antibody (ANCA)-associated vasculitis, and systemic
lupus erythematosus1, 2. Importantly, crescent formation within
the glomerulus appears to occur downstream of the original
inflammatory insult with common mechanisms that are inde-
pendent of the initial injury. This might be because the patho-
genesis of RPGN involves local factors as well as inflammatory
cells and immune mediators.
The proliferation of podocytes3, 4 and of parietal epithelial
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podocytes are glomerular epithelial cells that are normally
growth-arrested because of the expression of cyclin-dependent
kinase (CDK) inhibitors6–10. Under pathological conditions,
podocytes may undergo mitosis but fail to complete cell division.
Crescentic RPGN is an exceptional condition where podocytes
undergo a dysregulation of their differentiated phenotype and
start to proliferate and migrate resulting in the so-called “extra-
capillary glomerulopathy”.
Studies in human kidney biopsies3 and in a relevant mouse
model11 demonstrate that podocytes are dysregulated in RPGN;
they lose their typical cell markers and switch to a proliferative
phenotype. Convincing evidence for podocyte involvement in
RPGN has come from two studies, one in which podocyte-specific
deletion of the Vhl gene resulted in podocyte proliferation,
crescent formation, and the rapid onset of renal failure12, and the
other in which podocyte-specific deletion of the Egfr gene pre-
vented such features13. Numerous signaling pathways and pro-
teins can be activated downstream of EGFR activation, including
proteins of the signal transducer and activator of transcription
(STAT) family, namely STAT514 and STAT315. The STAT3-SH2
domain can directly bind phosphorylated EGFR at tyrosine 1068
and tyrosine 108616. STAT3 transduces signals from growth
factors and cytokines and plays an important role in develop-
ment, cell growth, prevention of apoptosis, proliferation, and
inflammation17.
MicroRNAs (miRNAs) are endogenous, short-length, single-
stranded non-coding RNAs that can disrupt gene expression by
inducing translation inhibition and mRNA degradation. Recent
evidence indicates that miRNAs may have a pivotal role in a
number of renal disorders18. MiRNA profiling in isolated glo-
meruli from mice with nephrotoxic serum-induced crescentic
nephritis (NTN) and control mice unraveled upregulation of
miR92a. MiR92a belongs to the first discovered microRNA
cluster as a potential human oncogene19. The miR-92a family is
related to the formation of vascular endothelial cells20, 21. Aber-
rant expression of miR-92a family was detected in multiple
cancers, and the disturbance of miR-92a family was related with
tumorigenesis and tumor development22.
Here we report that the abundance of miR-92a is high in
kidney biopsies from patients diagnosed with crescentic RPGN,
especially within podocytes, as well as in mice exposed to NTN.
We next investigated the role of miR-92a in primary cultures of
podocytes as well as in the NTN model of crescentic RPGN.
Given the promoter region of the miR-17/92 gene contains a
highly conserved functional STAT3-binding site23, we examined
miR-92a expression dependency on STAT3 in podocytes and in
the context of severe extracapillary glomerulonephritis. We have
discovered that the STAT3−miR-92a activation governs a ded-
ifferentiation program in podocytes with acquisition of pro-
liferative capability. We went on to examine the involvement
miR-92a activation in the glomerular injurious process. Condi-
tional podocyte-specific miR-92a deletion reduces albuminuria
and glomerular injury and fully prevents renal failure after NTN.
Inhibition of miR-92a in vitro upregulates the expression of its
direct target the CDK inhibitor p57Kip2 that regulates the podo-
cyte cell cycle, and results in impairment of cell proliferation. To
translate our findings to a potentially novel therapy for RPGN, we
find that specific blockade of miR-92a in vivo markedly prevents
albuminuria, crescent formation, and renal failure even when this
strategy is initiated in a therapeutic manner after the onset of
NTN.
Results
Glomerular miR-92a induction in mouse nephrotoxic nephri-
tis. We carried out miRNA profiling in isolated decapsulated
glomeruli from NTS-challenged and control mice. We detected
several significantly and differentially expressed miRNAs on day
10, a time when the onset of crescent formation is detectable with
proliferating (Ki67+) podocytes (Fig. 1a). We then refined our
analysis to select miRNA species that were enriched in podocytes
using freshly sorted podocytes from nephritic and control mice
with podocyte-specific GFP expression (NPHS2-Cre x mT/mG).
MiR-92a was selectively induced in glomerular epithelial cells in
nephritic mice as demonstrated both by in situ hybridization in
WT1-expressing cells in kidney sections (Fig. 1b) and by RT-
qPCR in freshly sorted podocytes from NPHS2-Cre x mT/mG
mice (Fig. 1c).
High expression of miR-92a in human kidneys with RPGN. To
evaluate the clinical relevance of our findings, we analyzed miR-
92a expression in kidney biopsies from patients with RPGN and
control patients with non-proliferative glomerulopathies
(Table 1). Whereas miR-92a labeling was weak and restricted to
the endothelium in control human kidneys (non-crescentic glo-
merular diseases) (Fig. 1d), miR-92a was significantly upregulated
in kidney biopsies from patients with RPGN, regardless of
etiology. In situ hybridization revealed the expression of miR-92a
in glomerular epithelial cells of patients with RPGN, particularly
in podocytes and crescents, and to a lesser extent in parietal
epithelial cells (Fig. 1d). These results were independently con-
firmed by RT-qPCR analysis in laser capture microdissected
glomeruli showing a 3.5- to 4-fold increase of miR-92a to
U6snRNA ratio in RPGN cases compared to cases diagnosed with
non-proliferative glomerular diseases (Fig. 1e).
This prominent induction of miR-92a was further demon-
strated in WT1-expressing podocytes in kidney biopsies from
individuals diagnosed with crescentic RPGN but not in those
patients with non-proliferative glomerulopathies such as mem-
branous nephropathy (Fig. 1f). In situ hybridization of U6snRNA
Fig. 1 Increased miR-92a expression in crescents and podocytes during nephrotoxic nephritis and human crescentic glomerulonephritis. a Representative
microRNA profiling on dynabeads-isolated glomeruli from control or NTS-challenged mice (NTN). Values are means± s.e.m., *p< 0.05 vs. control
condition (n= 3 samples per condition). b Relative abundance of miR-92a assessed by RT-qPCR in sorted podocytes from normal healthy mice (control)
and NTS-challenged mice (NTN). Values are means± s.e.m., *p< 0.05 vs. control condition (n= 5 mice per condition). c Double miR-92a in situ
hybridization (blue staining) and WT1 staining (brown staining) of kidney sections from normal mice (control) and NTS-challenged mice (NTN). Pictures in
the bottom show a higher magnification of the top panel. Scale bars, 10 μm. d miR-92a in situ hybridization of kidney sections from random biopsies from
individuals diagnosed with non-crescentic glomerulopathies, including minimal change disease (MCD) and membranous nephropathy (MN), and from
patients with RPGN of various etiologies including stage III and IV lupus nephritis (LN), microscopic polyangiitis (MPA), and granulomatosis with
polyangiitis (GPA). Scale bars, 50 μm. The lower panel shows higher magnification of middle panels (black box). Black stars (*) show miR-92a-positive
cells. e RT-qPCR analysis of the relative abundance of miR-92a in microdissected glomeruli from four patients with non-crescentic glomerulopathies (black
bars) and six patients with crescentic RPGN (white bars). Values are means± s.e.m., *p< 0.05 vs. non-crescentic glomerular diseases. f Fluorescent in situ
hybridization of miR-92a (red) and WT1 (green) on patients biopsies described in d. Bottom panel shows higher magnification of top panel (white box).
White arrows show colocalization of WT1-positive cells and miR-92a expression. Scale bars, 50 μm. Statistical analysis: Mann–Whitney test to compare
two groups
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was used as a control (Supplementary Fig. 1a). Moreover,
utilizing RT-qPCR analysis of miRNA in whole kidney biopsy
sections (a more practical alternative to laser capture micro-
dissection of glomeruli or in situ hybridization), we showed that
the expression of miR-92a was 2- to 7.5-fold higher in samples
from patients with RPGN than in those from patients with other
chronic proteinuric glomerular diseases (minimal change disease
(MCD) and membranous nephropathy (MN)) (Supplementary
Fig. 1b) with no overlap of relative miR-92a levels between the
RPGN and non-RPGN groups. Interestingly, a similar pattern of
miR-92a expression was observed in all kidney samples from
patients with RPGN regardless of etiology.
As miR-92a is part of the miR-17–92 cluster that encodes a
polycistronic transcript that produces six individual mature
miRNAs24, we expected increased glomerular expression of all
members of the cluster. Surprisingly, miR-92a was the only
member to be dysregulated in human (Supplementary Fig. 1c)
and murine RPGN (Supplementary Fig. 1d).
These studies show that miR-92a is highly abundant in
conditions associated with glomerular epithelial cell proliferation
and crescent formation.
miR-92a expression is modulated downstream of the STAT3
cascade in podocytes. We focused our analysis on STAT3-
dependent miRNAs given our evidence for EGFR and STAT3
activation in freshly isolated glomeruli of NTS-challenged and
control mice. Phosphorylation of EGFR at tyrosine 1068, a
marker of EGFR activation, and phosphorylation of STAT3 at
tyrosine 705, a marker of STAT3 activation, were stimulated by
NTS administration (Supplementary Fig. 2a, b). Furthermore,
nephritic mice displayed a 10-fold increase in podocyte nuclear
localization of phosphorylated STAT3 (pY705) compared to
healthy mice (Supplementary Fig. 2c, d). Notably, STAT3 acti-
vation was recently shown to aggravate experimental crescentic
glomerulonephritis25 and is also known to activate several
Table 1 Patients clinical details








F 29 MCD Control Relapse Corticosteroids 1.07 79
F 30 MCD Control Relapse No treatment 0.19 73
M 66 MCD Control First episode No treatment 0.56 55
F 31 MCD Control First episode No treatment NA 94
F 30 MN Control First episode No treatment 0.08 89
M 46 MN Control First episode No treatment 0.6 90
M 50 MN Control First episode No treatment >3 72
M 62 MPA RPGN First episode No treatment 0.1 63
MPO-ANCA-
positive
M 78 MPA RPGN First episode Corticosteroids 0.23 39
PR3-ANCA-
positive
M 52 MPA RPGN First episode No treatment 0.41 47
MPO-ANCA-
positive
F 46 MPA RPGN First episode No treatment 0.26 18
MPO-ANCA-
positive
M 47 MPA RPGN First episode No treatment 0.27 6
MPO-ANCA-
positive
F 58 MPA RPGN First episode No treatment Traces 6
MPO-ANCA-
positive
M 44 MPA RPGN First episode No treatment 0.08 55
MPO-ANCA-
positive
M 68 GPA RPGN First episode Corticosteroids 0.15 58
PR3-ANCA-
positive
M 71 GPA RPGN First episode No treatment 0.56 75
PR3-ANCA-
positive
M 55 GPA RPGN Relapse Corticosteroids 5 52
PR3-ANCA-
positive
F 35 LN (class IV) RPGN Relapse Corticosteroids 0.34 35
F 27 LN (class IV) RPGN Relapse Corticosteroids 0.26 41
M 17 LN (class IV) RPGN First episode No treatment 0.13 37
F 41 LN (class III) RPGN Relapse Corticosteroids 0.19 25
F 25 LN (class III) RPGN First episode No treatment 0.25 50
Patients’ characteristics at the time of the kidney biopsy used in the study. The eGFR is calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
MCD minimal change disease; MN membranous nephropathy; MPA microscopic polyangiitis; GPA granulomatosis with polyangiitis (GPA); ANCA anti-neutrophil cytoplasmic antibodies; MPO
myeloperoxidase; PR3 proteinase 3; LN class III and class IV lupus nephritis, control for non-crescentic glomerular disease and RPGN for crescentic RPGN
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miRNAs in a number of proliferative disorders26–29. We focused
our bioinformatics analysis on those STAT3-dependent miRNAs
whose predicted targets control cell proliferation (Supplementary
Fig. 2e). MiR-92a was the most differentially upregulated candi-
date fulfilling these criteria. A bioinformatics screen for STAT3-
binding sites in the promoter of the chromosome 13 open reading
frame 25 (C13orf25) containing the miR-17–92 cluster revealed a
highly conserved binding site. Furthermore, this binding site for
STAT3 was previously functionally confirmed by Brock et al. with
a reporter gene assay study. The authors showed a down-
regulation of luciferase activity when the predicted STAT3-
binding site on C13orf25 promoter was mutated (mutated pro-
moter construct)23.
We next investigated upstream activators of the STAT3-miR-
92a cascade in primary cultures of podocytes. STAT3 signaling is
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Fig. 2 Inhibition of miR-92a in podocytes upregulates its target p57 and impairs proliferation. a RT-qPCR analysis of the relative abundance of miR-92a in
podocytes transfected with an anti-miR-control (anti-miR-ctrl) or an anti-miR-92a. Values are normalized to U6snRNA and are relative to control (non-
transfected cells). b, c Representative pictures (b) and quantification (c) of podocyte proliferation assay involving decapsulated mouse glomeruli. Podocyte
proliferation was assessed after 4 days. Scale bars, 50 μm. d RT-PCR analysis of Ki67 mRNA abundance in intact and anti-miR-ctrl primary podocytes or in
anti-miR-92a primary podocytes. e Dual luciferase assay wild-type or mutated p57 3′UTR in HEK293 cells transfected with pre-miR-ctrl, pre-miR-92a, or
pre-miR-126. n= 2 independent experiments (each experiment assayed each condition in triplicate). p57 3′UTR miR-92a-binding sequence binding site is
indicated in bold and mutated sequence is labeled in red. ***p< 0.001 vs. 3′UTR +Pre-miR- ctrl. f, g Western blot analysis (f) and quantification of p57
protein abundance (g) in untreated or anti-miR-ctrl primary podocytes vs. in anti-miR-92a primary podocytes. Tubulin is shown as a loading control.
h Staining of p57 protein (green) in podocyte outgrowths. DAPI-stained nuclei (blue). Adherent glomeruli are indicated by arrows. Scale bars, 100 μm.
Statistical analysis: Kruskal–Wallis one-way analysis of variance followed by Dunn’s multiple comparaison test. Values are means± s.e.m. (n= 4 per
group). *p< 0.05, **p< 0.01, and ***p< 0.001 vs. control podocytes (control)
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Fig. 3 p57Kip2 expression is lost during RPGN and p57Kip2 silencing decreases podocyte proliferation. a, b Western blot analysis (a) and quantification (b)
of p57 on magnetic beads isolated glomeruli from unchallenged (control) or NTS-challenged (NTN) mice. Values are means± s.e.m. (n= 5 per group). *p
< 0.05 vs. control. c Immunostaining of p57 (strong brown staining) and immunofluorescent p57 (red)/WT1 (green) staining in kidney sections from
normal mice (control) and NTS-challenged mice (NTN). Scale bars, 10 µm. d Quantification of p57-positive cells per glomerular section in mice described
in a. e Representative photomicrographs of p57 immunostaining (strong brown staining) in kidney sections from random biopsies from individuals
diagnosed with non-crescentic glomerulopathies, including minimal change disease (MCD) and membranous nephropathy (MN), and from patients with
RPGN of various etiologies including stage III and IV lupus nephritis (LN) and microscopic polyangiitis (MPA). Scale bars, 50 µm. f Quantification of p57-
positive cells per glomerular section in biopsies described in e. Values are means± s.e.m. *p< 0.05 vs. non-crescentic glomerular diseases. g
Representative pictures of p57 staining (red) and podocyte proliferation assay in control cells (non-transfected) or transfected with a control siRNA
(siRNA-control) or a siRNA for p57 (siRNA-p57). DAPI-stained nuclei (blue). Top panel (scale bars, 50 μm); bottom panel (scale bars, 100 µm). h
Quantification of podocyte proliferation assay involving decapsulated mouse glomeruli. Podocyte proliferation was assessed after 4 days. Values are
means± s.e.m. (n= 6 per group). ***p< 0.001 vs. non-transfected cells. Statistical analysis: Kruskal–Wallis one-way analysis of variance followed by
Dunn’s multiple comparaison test or Mann–Whitney test to compare groups. Values are means± s.e.m
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or IL-633–35. As previously found, we measured activation of the
Hbegf gene in cultured podocytes, as found in crescent13. We also
measured a fourfold increase in IL6 mRNA expression by
primary podocytes undergoing a dedifferentiation and prolifera-
tive program (Supplementary Fig. 3a).
To examine whether IL-6 and EGFR activate STAT3 in
podocytes, we blocked IL-6 and EGFR in cultured primary
podocytes and performed western blotting to determine STAT3
phosphorylation (Tyr705), which is a marker of STAT3
activation. Cultured podocytes displayed autocrine constitutive
STAT3 (Supplementary Fig. 3b, c, d, f) and EGFR activation
(Supplementary Fig. 3d, e). We found that both addition of
exogenous recombinant IL-6 or HB-EGF-stimulated STAT3
phosphorylation and miR-92a expression (Supplementary Fig. 3g,
h). Furhermore, an anti-mIL-6 monoclonal antibody and a
specific inhibitor of EGFR kinase, AG1478 impaired STAT3
phosphorylation, miR-92a expression, and Ki67 levels (Supple-
mentary Fig. 3f, h, i). These data indicate that the IL-6 receptor
(IL-6R) and EGFR pathways are tonically activated by autocrine
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findings suggest that both EGFR and IL-6R stimulate the STAT3-
miR-92a cascade in activated proliferating podocytes.
To further confirm the mechanisms whereby miR-92a is
induced in vivo, we went on to abolish STAT3 expression
specifically in podocytes by generating mice with floxed Stat3 and
podocyte-specific expression of Cre (Pod). Double staining of
STAT3 protein and podocalyxin (a cell surface marker of
podocytes) on kidney sections revealed marked constitutive
expression of STAT3 in podocytes of glomeruli from nephritic
Pod-Stat3 WT mice but STAT3 staining was almost absent in
podocytes from Pod-Stat3 lox mice (Supplementary Fig. 4a).
Deletion of STAT3 was also confirmed in cultures of primary
podocytes isolated from Pod-Stat3 lox or Pod-Stat3 WT mice for
which the prurity of the primary culture was confimed by
examining podocin, nephrin, and WT1 staining (Supplementary
Fig. 4b); western blot analysis showed ~90% reduction in STAT3
expression in cultured podocytes from Pod-Stat3 lox compared to
controls (Supplementary Fig. 4c, d).
Genetic Stat3 allele deletion limited miR-92a expression in
primary culture of podocytes (Supplementary Fig. 4e). A similar
effect was observed in Pod-Stat3 WT cells treated with Stattic, a
pharmacological STAT3 inhibitor (not shown)36.
Given we had found STAT3 to be a strong modulator of miR-
92a in cultured podocytes, we studied the expression of miR-17/
92 in experimental NTN on Pod-Stat3 lox mice. MiR-92a
upregulation was confirmed in vivo by miR-92a RT-qPCR in
isolated glomeruli (Supplementary Fig. 4f) and by in situ
hybridization (Supplementary Fig. 4f, g) that showed a wide-
spread high abundance of miR-92a throughout glomerular
sections from NTS-challenged nephritic Pod-Stat3 WT mice,
particularly in glomerular epithelial cells. MiR-92a glomerular
expression was not induced in Pod-Stat3 lox mice despite NTS
challenge. Overall, miR-92a expression was significantly lower in
glomeruli isolated from Pod-Stat3 lox mice compared to that
measured in Pod-Stat3 WT podocytes.
miR-92a inhibition preserves p57Kip2 expression and lim-
its podocyte proliferation. To decipher the role of miR-92a in
podocyte function, we inhibited miR-92a expression in primary
cultures of podocytes (Fig. 2a). We established an in vitro assay
for podocyte crescent formation and measured outgrowth of
podocytes from isolated, decapsulated mouse glomeruli13. Both
podocyte outgrowth area and the abundance of Ki67 mRNA were
lower in podocytes transfected with anti-miR-92a than in control
cells transfected with an anti-miR control (Fig. 2b, c, d). There-
fore, miR-92a is involved in the regulation of podocyte pro-
liferation. We next searched for potential targets of miR-92a
using the target prediction algorithms miRWalk and TargetS-
can37, 38. We focused on genes relevant to the maintenance of
podocyte quiescence. Among potential candidates, the p57/Kip2/
Cyclin-dependent kinase inhibitor 1C is a member of the Cip/Kip
family and is a strong inhibitor of several G1 cyclin/Cdk
complexes and a negative regulator of cell proliferation39, 40.
Overexpression of p57Kip2 leads to G1 phase cell cycle arrest. This
protein has been shown to be constitutively expressed in mature
podocytes10, 41, an observation that we confirmed. Interestingly,
impairment in p57Kip2 expression during glomerular disease is
associated with a high rate of podocyte proliferation6. p57Kip2
displays a 3′UTR miR-92a-binding sequence. Utilizing a 3′UTR
luciferase assay, we confirmed that miR-92a directly targets
p57Kip2 (Fig. 2e and Supplementary Fig. 6a, b, c). Furthermore,
we showed by western blot and immunofluorescence that the
abundance of p57Kip2 was higher in anti-miR-92a-transfected
podocytes and correlated with a lower rate of podocyte pro-
liferation (Fig. 2f, g, h).
We next studied whether the p57Kip2 expression pattern in
podocytes during RPGN corresponded to the loss of expression
observed in proliferating cultured podocytes with high miR-92a
expression. We found significantly reduced p57Kip2 abundance in
glomerular lysates from NTS-challenged mice (Fig. 3a, b) and
immunostaining for p57Kip2 in kidney sections of mice confirmed
this loss was exclusively from the podocytes (Fig. 3c, d).
Importantly, in keeping with our pre-clinical findings, we found
almost complete disappearance of p57Kip2 expression in glomer-
uli from individuals diagnosed with crescentic RPGN due to
ANCA vasculitis and lupus nephritis (Fig. 3e, f).
In order to investigate whether downregulation of p57Kip2 is
associated with defective cell cycle exit of podocytes, we knocked
down p57Kip2 in primary mouse podocytes cultures (Fig. 3g and
Supplementary Fig. 6d, e) that significantly boosted podocyte
proliferation (Fig. 3g, h). These data indicate that p57Kip2 is a
“master safeguard” of podocyte quiescence.
miR-92a deletion prevents crescentic glomerulonephritis and
renal failure. To determine if miR-92a expression in podocytes
in vivo is necessary for crescent formation and renal failure, we
selectively deleted miR-92a from podocytes. We used a condi-
tional expression model (Tet-On system) to achieve temporal
podocyte-specific deletion of the miR-92a gene in mice. Mice of
all genotypes were born at the expected Mendelian frequency and
appeared healthy. Ten weeks after doxycycline administration,
marked reduction of miR-92a abundance in podocytes was
achieved (Fig. 4a), with most of residual signal being in endo-
thelial cells. Overall, a ~50% reduction in relative miR-92a
expression was achieved in glomeruli (Fig. 4b). Podocin-rtTA-
Tet-O-Cre miR-92a loxP/loxP (iPod-miR92a lox) mice had nor-
mal kidney histology (Supplementary Fig. 7) and albuminuria
that was within the physiological range (Fig. 4c). iPod-miR92a lox
males and Podocin-rtTA-Tet-O-Cre miR-92a wt/wt (iPod-
miR92a wt) gender-matched littermates were subjected to severe,
life-threatening NTN with high-dose NTS. Podocyte-specific
deletion of miR-92a-alleviated albuminuria (Fig. 4c), crescent
formation (Fig. 4d, e), the rise in BUN (Fig. 4f), and significantly
protected mice from p57Kip2 loss in podocytes (Fig. 4g–i).
Fig. 4 miR-92a-specific deletion in podocytes reduces nephrotoxic nephritis. a Fluorescent in situ hybridization of miR-92a (red) and WT1 (green) on
kidney sections from NTS-challenged iPod-miR92aWT mice and iPod-miR92a lox mice. DAPI-stained nuclei (blue). Right panel shows higher magnification
of the left panel (white box). Scale bars, 50 μm. b RT-qPCR analysis of the relative abundance of miR-92a in freshly isolated glomeruli from NTS-challenged
iPod-miR92a WT mice and NTS-challenged iPod-miR92a lox mice. c Urinary albumin excretion rates at baseline and 10 days after NTS injection. d Masson
trichrome- and silver-stained kidney sections of glomeruli from NTS-challenged iPod-miR92a WT mice and iPod-miR92a lox mice at day 10 after NTS
injection. Scale bars, 10 μm. e Proportion of crescentic glomeruli in NTS-challenged iPod-miR92a WT and iPod-miR92a lox mice at day 10 after NTS
injection. f Blood urea nitrogen concentration at day 10 after NTS injection in iPod-miR92aWT and iPod-miR92a lox mice. g Immunostaining of p57 (strong
brown staining, *) in kidney sections from mice described in a. Scale bars 10 µm. h Quantification of p57-positive cells per glomerular section in mice
described in a. i Representative photomicrophotographs of dual immunofluorescent satining of p57 (red) and WT1 (green) in kidney sections from mice
described in a. Statistical analysis: Mann–Whitney test to compare two groups. Values are means± s.e.m. (n= 7 per group). *p< 0.05, **p< 0.01 vs. iPod-
miR-92a WT mice
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Anti-miR92a protects from crescentic glomerulonephritis and
kidney failure. Our data suggest that RPGN is associated with
increased miR-92a expression and activity in podocytes and that
this may be pathogenic in disease progression. Hence, we went on
to test whether pharmacological inhibition of the miR-


















































































































































































Fig. 5 Silencing miR-92a prevents kidney injury in a mouse model of nephrotoxic nephritis. a Study design of the in vivo preventative antagomir experiment.
b RT-qPCR analysis of the relative abundance of miR-92ain freshly isolated glomeruli from normal mice (control), NTS-challenged mice (NTN), NTS-
challenged mice treated with anti-miR-control (NTN + anti-miR-ctrl) and NTS-challenged mice treated with anti-miR-92a (NTN + anti-miR-92a) after
10 days. All values are normalized to U6snRNA and are relative to control. Values are means± s.e.m. (n= 4 per group). *p< 0.05 vs. control, #p< 0.05 vs.
NTN alone. c Representative photomicrographs of p57 staining (scale bars, 10 µm), Masson trichrome- (scale bars, 20 µm), silver-stained kidney sections
(scale bars, 10 µm) and transmission electron microscopy (scale bars, 0.5 µm) from groups of mice described in a. d Quantification of p57Kip2-positive cells
per glomerular section in mice described in a. e Proportion of glomerular crescents in kidney sections, f albuminuria, and g blood urea nitrogen
concentrations in mice as described in a. Values are means± s.e.m. (n= 4 per group). *p< 0.05 vs. control, #p< 0.05 vs. NTN alone. Statistical analysis:
Kruskal–Wallis one-way analysis of variance followed by Dunn’s multiple comparaison test
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chemically engineered oligonucleotides, termed “antagomirs”
(anti-miRs), efficient and specific silencers of endogenous miR-
NAs in mice. Anti-miRs are taken up into the kidney cortex after
intravenous injection into mice42.
We first administered an anti-miR-92a strategy in a pre-
ventative fashion. Anti-miR-92a injections to mice inhibited miR-
92a expression in glomeruli during NTN (Fig. 5a, b) without
modifying the expression of other miRNAs from the 17–92
cluster (not shown). Induction of NTN was associated with a low
abundance of p57Kip2 in podocytes that was partially but
significantly rescued by delivery of anti-miR-92a (Fig. 5c, d and
Supplementary Fig. 8a). Importantly, NTS-induced glomerular
injury was less severe in mice that received anti-miR92a (NTN
+anti-miR92a) than in mice that received a control anti-miR
(NTN+anti-miR-ctrl) or in mice that received vehicle alone



































































































































































































Fig. 6 miR-92a in vivo silencing abolishes nephrotoxic nephritis development. a Study design of the in vivo antagomir experiment. b Relative miR-92a
expression in dynabeads-isolated glomeruli from normal mice (control), NTS-challenged mice (NTN), NTS-challenged mice treated with anti-miR-control
(NTN + anti-miR-ctrl), and NTS-challenged mice treated with anti-miR-92a (NTN + anti-miR-92a) after 10 days. All values are normalized to U6 and are
relative to control. Values are means± s.e.m. (n= 5 per group). *p< 0.05 vs. control, #p< 0.05 vs. NTS alone. c Urinary albumin excretion rates at day 4
(before antagomir injection) and at day 10 after NTS injection. d Blood urea nitrogen concentration at day 10 after NTS injection in control or NTS-
challenged mice. e Silver-stained kidney sections of mice described in b. Scale bars, 10 µm. f Proportion of crescentic glomeruli in kidney from mice
described in b. Values are means± s.e.m. (n= 10 mice per group). g Representative immunostaining of p57 (strong brown staining) in kidney sections from
mice described in a. Scale bars, 10 µm. h Quantification of p57-positive cells per glomerular section in mice described in a. Values are means± s.e.m. (n=
10 per group). *p< 0.05, #p< 0.05 vs. NTS alone (NTN). Statistical analysis: Kruskal–Wallis one-way analysis of variance followed by Dunn’s multiple
comparaison test
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lower in NTN+anti-miR92a mice than in either control condition
(Fig. 5c, e). This improvement in kidney structure was also
reflected by less severe damage to the podocyte ultrastructure in
anti-miR-92a-injected mice relative to untreated and anti-miR-
ctrl injected littermate controls (Fig. 5c). These improved
structural parameters corresponded to improved functional
parameters: urinary albumin excretion was lower (Fig. 5f), and
kidney dysfunction minimal (Fig. 5g) in anti-miR-92a-treated
mice.
We next administered anti-miR-92a, on day 4 after infusion of
NTS (Fig. 6a). This time-point was chosen as it is clinically
relevant, associated with nephrotic range albuminuria and high
serum creatinine and BUN. As previous, this regimen was
compared with the effects of vehicle alone and with the
administration of an anti-miR-ctrl. Anti-miR-92a given after
NTS still effectively inhibited glomerular miR-92a levels at day 10
(Fig. 6b) and these mice displayed a marked reduction in
albuminuria (Fig. 6c). Furthermore, whereas vehicle-only-treated
mice (NTN) or anti-miR-ctrl-treated mice (NTN+anti-miR-ctrl)
developed rapid and life-threatening kidney failure, mice treated
therapeutically with anti-miR-92a had BUN levels within the
normal range (Fig. 6d). This functional protection conferred by
anti-miR-92a administration was associated with marked allevia-
tion of histologic damage as measured using silver staining of
renal cortex (Fig. 6e, f) and significantly preserved p57Kip2
expression in podocytes (Fig. 6g, h and Supplementary Fig. 8b).
Discussion
RPGN with extracapillary proliferation of epithelial glomerular
cells is an area of unmet clinical need. Despite current immu-
nosuppressive therapies, a significant number of patients with
RPGN fail to respond to treatment and their disease progresses to
end-stage kidney disease with its associated significant morbidity
and mortality. RPGN involves the response of podocytes to
immune injury. Therefore, better understanding of the mechan-
isms that regulate podocyte function are critical. Here we
explored the role of miRNAs. Furthermore, the mechanisms
whereby terminally differentiated, post-mitotic podocytes reenter
cell cycle upon immune-mediated stress are unknown.
Our data demonstrate the involvement of miR-92a in the
deleterious response to immune injury that leads to glomerular
destruction and functional demise. Our investigation further
identified a key miR-92a target, the p57/Kip2/Cyclin-dependent
kinase inhibitor 1C, which is involved in cell cycle regulation and
control of the quiescent state of podocytes.
MiR-92a is part of the miR-17–92 cluster, which contains six
miRNAs24. The human MIR17(MIR17HG) cluster has been
linked to developmental, apoptotic, and oncogenic pathways in
other organs, and the locus is conserved between mouse and man.
Mice deficient for miR-17/92 die shortly after birth and have
cardiac and lung abnormalities. Thus, this cluster plays an
important role during development. Among the members in the
cluster, miR-92a is the least characterized. Whereas endothelial
miR-92a has been characterized with pro-inflammatory and anti-
angiogenic effects43–45, ours is the first description of epithelial
induction in post-mitotic cells. As miR-92a is part of the miR-
17–92 cluster that encodes a polycistronic transcript that pro-
duces six individual mature miRNAs24, we expected increased
glomerular expression of all members of the cluster. Surprisingly,
miR-92a was the only member to be dysregulated in human and
murine RPGN. In fact, this phenomenon was also previously
found in experimental atherosclerosis45. Moreover, these in vivo
data are consistent with the recent demonstration that expression
of individual miRNAs from pri-miR-17/92 is dynamically
regulated46.
MiR-92a was significantly overexpressed in human glomeruli
from patients with RPGN compared to those with other non-
proliferative glomerular diseases. This difference highlights the
difference in pathogenesis of these diseases, the former being
critically dependent on loss of podocyte post-mitotic quiescence.
However, miR-92a expression level did not correlate with histo-
logical variant of crescent (cellular vs. fibrocellular), proteinuria,
or kidney function. This may be explained by clinical hetero-
geneity in terms of stage of disease at the time of diagnosis or
relationship between miRNA expression and cell density. For
example, we observed intense miR92a expression in fully con-
stitued crescents and less in pseudo-crescents (when a paucity of
cells are proliferating) and fibrocellular cellular crescents (when
many epithelial cells have already disappeared).
We identified a miR-92a target relevant to podocyte prolifera-
tion. In contrast to immature podocytes, which proliferate during
glomerular development, differentiated podocytes have a quies-
cent phenotype47. This is required for podocytes to perform their
specialized functions47. Two independent target prediction algo-
rithms and luciferase assay identified p57Kip2 as a relevant miR-
92a target. The CDK inhibitor p57Kip2 regulates cell proliferation
and differentiation48. This protein is typically present in differ-
entiated and post-mitotic non-renal cells. Several groups observed
that the de novo expression of p57Kip2 in podocytes during
glomerulogenesis coincides with the acquisition of a terminally
differentiated quiescent phenotype6, 49. Loss of p57Kip2 expression
in podocytes is recognized as an early feature of proliferative
glomerular diseases and dedifferentiation in vitro3, 6, 8, 49–52,
although the mechanisms involved remained unclear.
Identifying p57Kip2 as a key effector of mi-92a in podocyte
drove us to test whether p57Kip2 participates in the extrinsic
stimuli-dependent abrogation of podocyte quiescence. Our results
suggest that a reduction in p57Kip2 protein, a brake on podocyte
cell cycle, contributes to trigger activation of crescent formation
in response to immune-mediated glomerular injury. We do not
exclude that there are other potential miR-92a targets involved in
the proliferative response of podocyte. For instance, the integrin
subunit alpha5 is a target of miR-92a in ischemic tissues20.
Alpha5 integrin subunit showed a gradual loss in early FSGS and
became undetectable in advanced FSGS53, meanwhile, its reg-
ulation in crescentic RPGN remain to be characterized. Change in
integrin pattern may be important for podocyte functions in this
setting, as shown in other conditions54, 55.
The combination of our results from in vitro experiments,
mouse models, and human tissues indicate that the high abun-
dance of miR-92a can initiate a cascade of podocyte-destabilizing
molecular events, starting with the downregulation of p57Kip2 and
proliferation. Mechanistically, binding of miR-92a to the target
region of p57Kip2 acts as negative regulator and causes a lack in
the p57Kip2 that is available for podocyte cell cycle resistance to
ambient mitogenic stimuli. Moreover, specific blockade of miR-
92a in vivo by an antagomir markedly prevented proteinuria,
crescent formation, and renal failure. Together, these findings
indicate that miR-92a control of podocyte phenotype may be a
general paradigm for proliferative extracapillary diseases.
Several animal studies have used antagomirs to block target
microRNA at a concentration ranging from 0.33 to 100 mg/kg of
body weight. A potential concern of using high doses of these
agents is that they may non-specifically block genes other than
the target. Since previous studies have shown that a dose of 8 mg/
kg produced an effective tissue response20, we chose a similar,
albeit slightly higher, dose for our own study. We felt that 12 mg/
kg of body weight would account for the potential loss of drug in
the urine of heavily nephrotic animals. Encouragingly, our results
revealed a threefold decrease in miR-92 levels in glomeruli with
this dose compared to the control antagomir. In contrast,
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expression levels of 5 other microRNAs, miR-17, -18a, -19a, -19b,
and -20a were not different between the two groups of mice, thus
suggesting both efficacy and specificity of our antagomir. Inter-
estingly, prolonged anti-92a blockade at higher dose for more
than 10 weeks did not display detectable side effects in mice45.
Another notable finding of our study is that STAT3 activation is
required to trigger miR-92a pathogenic expression. This may lead
one to consider anti-STAT3 strategies as anti-miR-92a options.
Meanwhile, from a therapeutic perspective, the identification of a
molecular target that is as cell-specific as possible may be
important to limit the undesired side effects associated with more
upstream ubiquitous targets such as STAT3.
Finally, we also provide proof of principle that delayed anti-
miR-92a strategy could display therapeutic actions on glomerular
function and structure in a severe model of RPGN. Although this
treatment showed a preventive effect in our mouse model, it
remains to be seen whether this holds true for human RPGN.
Furthermore, although most of the pathophysiological actions of
miR-92a were found in podocytes, it is important to note that
anti-miR-92a strategies would be expected to alleviate endothelial
inflammation, cardiac ischemia, and atherosclerosis45, potentially
important given the high risk of cardiovascular disease in indi-
viduals with RPGN56–59.
Methods
Animals. Mice with podocyte-specific GFP expression (NPHS2-Cre x mT/mG)
were obtained by crossing podocin-Cre-positive mice60 with mT/mG mice (Gt(2)
26Sortm4(ACTB-tdTomato,-EGFP)Luo/J)61 on a C57BL6/J background that were
purchased from The Jackson Laboratories (Bar Harbor, ME). Mice with podocyte-
specific disruption of Stat3 were generated by crossing podocin-Cre-positive mice
with Stat3 floxed mice62 on a C57BL6/J background. Age-matched littermates that
had no deletion of Stat3 in any cells were considered as controls. To generate a
time-specific and podocyte-specific knockout of miR-92a, we crossed mice carrying
reverse tetracycline transactivator protein under control of the podocin promoter
(iPod) with mice carrying the Tet-O-Cre transgene as previously described13, 63
and with mice carrying a loxP-flanked miR-92a allele64. Doxycycline was admi-
nistered for 3 weeks before administration of nephrotoxic serum after 1 week of
washout. Age-matched littermates that had no deletion of miR-92a in any cells
were considered as controls. Experiments were conducted according to the French
veterinary guidelines and those formulated by the European Community for
experimental animal use (L358-86/609EEC), and were approved by the Institut
National de la Santé et de la Recherche Médicale and local University Research
Ethics Committee (file 12–62, Comité d’Ethique en matière d’Expérimentation
Animale, Paris Descartes).
Induction of nephrotoxic nephritis. Nephrotoxic nephritis was induced in male
mice (10–12 weeks of age) by intravenous injection of 15 µl of sheep anti-
glomerular basement membrane (GBM) nephrotoxic serum (NTS), which was
diluted with 85 µl of sterile phosphate buffer solution as previously described65, 66.
Serum injections were repeated twice: once on day 2 at 6 µl/g of body weight and a
second time on day 3 at 7 µl/g of body weight.
Biochemical measurements in blood and urine. Urinary creatinine and blood
urea nitrogen (BUN) concentrations were analyzed by a standard colorimetric
method (Olympus AU400) at the Biochemistry Laboratory of Institut Claude
Bernard (IFR2, Faculté de Médecine Paris Diderot). Urinary albumin excretion was
measured using a specific ELISA assay for the quantitative determination of
albumin in mouse urine (CellTrend GmbH).
Human tissues. Formalin-fixed, paraffin-embedded renal tissue specimens were
obtained from the Hôpital Européen Georges Pompidou, Assistance Publique-
Hôpitaux de Paris, Paris, France. Human tissue was used after informed consent by
the patients and approval from, and following the guidelines of, the local Ethics
Committee (IRB00003888, FWA00005831). Renal biopsy specimens with sufficient
tissue for immunohistochemical evaluation after the completion of diagnostic
workup were included.
Histology. Kidneys were harvested and fixed in 4% formol or in Alcohol-Formol-
Acetic acid. Paraffin-embedded sections (5 μm thick) were stained by Masson’s
trichrome to evaluate kidney morphology and determine the proportion of cres-
centic glomeruli by a blind examination of at least 50 glomeruli per section. Silver
staining of paraffin sections was also used for quantification of crescents.
Immunohistochemistry and immunofluorescence. Deparaffinized kidney sec-
tions were incubated for 30 min at 95 °C in target retrieval solution (S1699, Dako),
then in peroxidase blocking reagent (S2001, Dako), were blocked in PBS containing
5% BSA, and were immunostained for phospho-STAT3 (Tyr705) (clone EP2147Y,
Millipore, 1:50), nephrin (GP2, Progen, 1:400), WT1 (ab15249, Abcam, 1:400)
STAT3 (D1A5, Cell Signaling Technology, 1:200), podocalyxin (AF1556, R&D
systems, 1:100), and p57Kip2 (Clone M-20, Santa Cruz Technology, 1:200). For
phospho-STAT3, and p57Kip2, staining was detected by Histofine reagents
(Nichirei Biosciences), which contained anti-rabbit (414341F) or anti-goat
(414161F) immune-peroxidase polymer for mouse tissue sections. WT1 and p-
STAT3 primary antibodies were followed by a secondary rabbit anti-goat IgG
AF488-conjugated antibody (Invitrogen, 1:400), p57Kip2 primary antibody was
followed by a secondary anti-goat IgG AF594 (Invitrogen, 1:400), nephrin primary
antibody was followed by a secondary anti-guinea pig IgG AF594-conjugated
antibody (Invitrogen, 1:400). Podocyte culture cells were immunostained for
podocin (ab50339, Abcam, 1:100), nephrin (ab58968, Abcam, 1:400), WT1
(ab15249, Abcam, 1:400), or p57Kip2 (Clone M-20, Santa Cruz Biotechnology,
1:200). The nuclei were stained using DAPI. Images were obtained with an
Axioimager Z1 apotome (Zeiss) with Axiovision microscopy software. For quan-
tification of p57-positive nuclei or p-STAT3-positive cells, 10 glomeruli per mice
and five randomly chosen mice from each group were examined to calculate the
number of stained nuclei.
miR-92a in situ hybridization. In situ hybridization was performed on 5 μm-thick
kidney paraffin-embedded sections cut and fixed in PFA 4% for 10 min. Then
sections were washed with 1× PBS and were acetylated for 10 min. After washes,
sections were incubated with protein kinase K (Sigma-Aldrich) for 10 min at 37 °C.
After subsequent washes, sections were incubated with hybridization buffer for 5 h
at room temperature. miRNA probes (miR-92a probe double-DIG labeled LNA
probes, Exiqon, final concentration 20 nM) were mixed with denaturation buffer
and added to the sections and were incubated over night at 56 °C. U6snRNA probe
(3′-DIG labeled LAN, probe, Exiqon) was used at 10 nM final concentration and as
a positive control. The following morning, sections were washed in successively
decreasing SSC buffers for 5 min at 56 °C (5× 1 time, 1× 2 times, 0.2× 3 times) and
were then washed. Sections were incubated for 1 h in blocking solution (B1 solution
+ 3% fetal calf serum + 0.1% Tween-20), and were then incubated with anti-DIG
AP antibody (Roche; 1:2000) over night at 4 °C. After washes, sections were
incubated with NBT/BCIP (Promega) in NTMT + levamisole (0,2 mM/L) for 48 h
in the dark at RT. NBT/BCIP was changed every 12 h. Slides were fixed in PFA 4%
for 30 min and mounted with Fluoprep mounting medium (Biomerieux).
For fluorescent in situ hybridization (FISH), sections were incubated twice in
freshly prepared 3% H2O2 for 3 min to inactive endogenous peroxidases after
fixation, acetylation, and incubation with proteinase K. Slides were then rinsed
three times in PBS. Then, sections were incubated with hybridization buffer for 1 h
at 37 °C. MicroRNA probes (miR-92a, 5′-3′–Digoxigenin-labeled Locked Nucleic
Acid probe, Exiqon, 100 nmol/L; U6snRNA, 3′-Digoxigenin-labeled Locked
Nucleic Acid probe, 2 nmol/L) were mixed with denaturation buffer and then
incubated with the sections over night at 56 °C. Washes with decreasing
concentrations of SSC were the same as for ISH. Then, slides were again twice
incubated in freshly prepared 3% H2O2 for 5 min and washed three times in PBS.
Blocking solution (Tris + 3% fetal calf serum + 1% BSA) was applied to slide for 1 h
at room temperature, then incubated in anti-DIG-FAB peroxidase (POD) (Roche)
diluted 1:400 in blocking solution for 1 h at room temperature. After washes with
PBS, TSA Plus Cy3 system working solution was applied onto the sections for 10
min at room temperature in the dark according to the manufacturer’s protocol
(PerkinElmer Life sciences). The slides were washed three times in PBS.
To assess whether miR-92a was localized specifically in glomerulus, sections
were processed for double fluorescence staining to visualize the simultaneous
localization of miR-92a (red; Cy3) and a primary antibody for WT1 (green;
AF488), a podocyte-specific marker. Sections were incubated in demasking citrate
buffer during 20 min at 95 °C and solution with a primary anti-WT1 antibody
(Abcam) was applied on slide over night at 4 °C. The next day, slides were twice
immerged in PBS and incubated with a secondary AlexaFluor488-conjugated
antibody (Invitrogen) during 1 h at RT or with a Histofine-AEC system (DAKO
and Nichirei Biosciences). Nuclei were stained with DAPI for FISH and sections
were mounted using a drop of Fluorescent mounting medium (DAKO).
Laser capture microdissection of glomeruli. Laser microdissection was per-
formed with a PALM® RoboSoftware 4.6 MicroBeam system (PALM Microlaser
Technologies, Zeiss Micro Imaging, Munich, Germany) coupled to an inverted
microscope Axio Observer.Z1. Serial 20 μm-thick cryosections, stored either at −80
°C for a maximum of 48 h or processed immediately, were spread onto poly-
ethylene naphthalate (PEN) membrane-coated slides (Carl Zeiss Micro Imaging,
Munich, Germany) previously treated for 20 min under UV exposure. After sec-
tions, the slide is stained with toluidine blue solution under RNase-free conditions.
Glomerular tufts were delineated using a graphical computer wizard and isolated
from surrounding tissue by laser catapulting into the cap of a single micro-
centrifuge Eppendorf Tube® filled with 20 μl of RLT plus buffer/1% NucleoGuard
reagent (Amsbio) for subsequent RNA isolation with the AllPrep DNA/RNA
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Micro Kit (Qiagen). One cap per “section collection” was used and caps were
replaced on their tube and stored on dry ice prior to RNA extraction.
Transmission electron microscopy procedure. Small pieces of renal cortex were
fixed in 4% glutaraldehyde, postfixed in 1% osmium tetroxide, and embedded in
epoxy resin. Ultrathin sections were counterstained with uranyl acetate and
examined in a JEOL 1011 transmission electron microscope with Digital Micro-
graph software for acquisition.
Glomeruli preparation and isolation of podocytes. We used the magnetic bead
method described by Takemoto et al. with appropriate modifications67. In brief,
dynabeads perfusion was performed through the abdominal aorta and harvested
kidneys were transferred in fresh Hank’s buffered salt solution (HBSS). Then,
kidneys were minced into 1-mm3 pieces using a scalpel in digest solution (col-
lagenase 210 U/ml (Gibco), DNase I 40 U/ml (Euromedex)) and incubated at 37 °C
for 15 min on a rotator (100 rpm) The solution was pipetted up and down with a
cut 1000 μl pipette tip every 5 min. After incubation, all steps were carried out at 4 °
C or on ice. The digested kidneys were gently pressed twice through a 100-μm cell
strainer and the flow through was washed extensively with HBSS. After spinning
down, the supernatant was discarded and the pellet resuspended in 2 ml HBSS.
These tubes were inserted into a magnetic particle concentrator and the separated
glomeruli were washed five times. Glomeruli were lysed in RIPA buffer for protein
analysis or in Trizol for RNA study. For podocyte isolation, in a second digestion
step, glomeruli were enzymatically and mechanically disrupted to yield a single cell
suspension. Subsequently, green fluorescent protein (GFP)-positive podocytes from
NPHS2-Cre x mT/mG animals were separated from the GFP-negative non-
podocyte glomerular fraction by fluorescence-activated cell sorting (FACS) as
published68.
Glomeruli isolation for culture of primary podocytes and in vitro assays.
Magnetic beads infused-mouse kidneys were extracted, minced, and digested in 2
mg/ml collagenase I solution (Gibco) in RPMI 1640 (Invitrogen) at 37 °C for 3 min,
then filtered through a 70-µm cell strainer and once more through a 40-µm cell
strainer. The homogenate was centrifuged at 720×g for 6 min and the cells were
plated. Podocyte primary cultures consisted of freshly isolated glomeruli plated in
6-well dishes in RPMI 1640 (Invitrogen) supplemented with 10% fetal calf serum
(Biowest) and 1% penicillin–streptomycin (Invitrogen). Purity of culture of dif-
ferentiated primary podocytes was verified as previously described13, 69 and shown
in Supplementary Fig. 3b. Podocyte primary cultures used in this study was always
P0. The outgrowth of podocytes started between days 2 and 3. Podocyte outgrowth
area was quantified at day 4 using ImageJ software. Differentiated podocytes were
exposed to HB-EGF (10 ng/ml, Preprotech), AG1478 (1 µM, Calbiochem), anti-
mIL-6 monoclonal antibody MP5-20F3, monoclonal rat IgG1, κ isotype control
immunoglobulin (both functional grade purified, 10 µg/ml, eBiosciences), Stattic (2
µM, Calbiochem), or recombinant IL6 (10 ng/ml, Preprotech) for 16 h. After sti-
mulation, podocytes were scrapped in Phosphosafe buffer (Novagen) for protein
extraction or in Trizol (Invitrogen) for total RNA extraction.
miR-92a in vitro modulation. MicroRNA-92a inhibition was achieved in vitro by
transfecting primary culture podocytes with anti-miR-92a inhibitor using Hiperfect
transfection reagent (Qiagen). Anti-miR-Control was used as a control (All from
Ambion, 50 nM).
p57Kip2 3′UTR luciferase assay. For validation of p57 as a target of miR-92a,
3′UTR or mutated 3′UTR of mouse p57Kip2 were cloned into a mammalian
expression vector with dual luciferase reporter system (GeneCopoeia). HEK293
cells were transfected using Hiperfect (Qiagen). Transfections were performed
using 1 μg dual luciferase reporter plasmids and a final concentration of 100 nM
synthetic miR-92a mimic, or miR-126 as an irrelevant miRNA mimic (Applied
Biosystems). Twenty-four hours after transfection, dual luciferase assays were
performed using Luc-Pair miR luciferase assay kit (GeneCopoeia) according to
the manufacturer's instructions. Firefly luciferase activity was normalized to
Renilla luciferase expression control.
p57Kip2 silencing in vitro. p57Kip2 was silenced using ON-TARGETplus mouse
p57 siRNA SMARTpool (Dharmacon). Primary podocytes were transfected with
50 nM ON-TARGETplus mouse p57 siRNA SMARTpool using Hiperfect follow-
ing the manufacturer’s instructions over night. Thereafter, medium was changed
and cells were harvested after 72 h.
Western blotting. Proteins were extracted from glomeruli or podocytes with lysis
buffer and were quantified by BCA protein assay (iNtRON Biotechnology). Sam-
ples were resolved on 4–12% Bis-Tris Criterion XT gels (Bio-Rad) then transferred
to a polyvinylidene difloride membrane. Membranes were incubated with the
appropriate primary antibodies: rabbit anti-phospho-EGFR (Tyr1068) (D7A5, Cell
Signaling Technology, 1:1000), rabbit anti-EGFR (D38B1, Cell Signaling Tech-
nology, 1:1000), rabbit anti-STAT3 (D1A5, Cell Signaling Technology, 1:1000),
rabbit anti-phospho-STAT3 (Tyr705) (D3A7, Cell Signaling Technology, 1:1000),
goat anti-p57Kip2 (Clone M-20, Santa Cruz Biotechnology, 1:500). Protein loading
was monitored by the rat anti-tubulin antibody (ab6160, Abcam, 1:5000). Sec-
ondary antibodies were donkey anti-rabbit HRP and donkey anti-goat HRP (GE
Healthcare Life Sciences) with no cross reaction to sheep serum. Antigens were
detected by enhanced chemiluminescence (Supersignal West Pico, Pierce) using a
LAS-4000 imaging system (Fuji). Densitometric analysis with ImageJ software was
used for quantification. The uncropped versions of western blotting are shown in
Supplementary Fig. 10.
Real-time PCR. Total RNA was extracted from mice glomeruli, cultured podo-
cytes, or human biopsies with Trizol reagent according to the manufacturer’s
instructions (Invitrogen). Total RNA was reverse transcribed into cDNA using the
Quantitect Reverse Transcription kit (Qiagen). cDNA and standards were ampli-
fied with the Maxima SYBR Green/Rox qPCR mix (Fermentas) using an ABI
PRISM thermo cycler. The comparative method of relative quantification (2–ΔΔCT)
was used to calculate the relative expression level of each target gene. Mouse or
human GAPDH was used as an internal control. The data were presented as the
fold change in gene expression. The following oligonucleotides served as primers:
Mouse Ki67 forward 5′- CCTCAAAAGCAGACGAGCAAGA-3′, Mouse Ki67
reverse 5′- GAGAGTTTGCATGGCCTGTAGT-3′.
Following extraction by Trizol extraction, miRNA expression was determined
using Taqman miRNA assay (Life Technologies) according to the manufacturer’s
protocols. U6snRNA was used as an endogenous control. Total miR content
analysis of isolated glomeruli from control mice or NTS-challenged mice was
performed with the miRCURY LNATM Universal RT microRNA PCR Mouse&Rat
panel I+II (Exiqon).
In vivo miR-92a inhibition in mice. For preventive strategy, antagomiR treatment
(12 mg/kg) was started 3 days before NTS injection. AntagomiRs (VBC Biotech,
Vienna) were delivered by retro-orbital IV injections under brief anesthesia. Sec-
ond and third injections were performed on days 1 and 3 accompanying the NTS
injection. For curative strategy, antagomir were injected on days 4, 5, and 8 after
NTS. A scramble antagomiR (Antagomir-Control) was used as control. The
sequences (AntagomiR-Control (anti-miR-ctrl): 5′-AAGGCAAGCUGACCCU-
GAAGUU-3′ and antagomiR-92a (anti-miR-92a): 5′-CAGGCCGGGACAA-
GUGCAAUA-3′) were obtained from a previously published study20. In the miR-
92 antagomir and control antagomir, the 2′O RNA base are methylated and the
first two bases and the last three bases are phosphorothiated to increase the stability
of antagomir and hence protect it from degradation. In addition, a cholesterol-TEG
was added at the 3′ for easy entry of the antagomir to the cells. AntagomiR-Control
and antagomiR-92a were previously successfully used in vivo following adminis-
tration in kidneys42, 70. Saline-treated mice were used as a control of the scramble
antagomiR.
Statistical analyses. All values were expressed as means + s.e.m. When sample
size was less than five per group, exact, two-sided comparisons were performed
with exact test using StatXact 8.0 software (Cytel Software Corporation, Cambridge
MA, USA). In other cases, the two-tailed Mann–Whitney test, was used as
appropriate. For experiments with more than two subgroups, the nonparametric
Kruskal–Wallis ANOVA followed by Dunn's multiple comparison test were used.
Values of p < 0.05 were considered significant. Statistical analyses were calculated
using Prism v5.04 software (GraphPad Inc, La Jolla, CA, USA).
Data availability. The authors declare that data supporting the findings of this
study are available within the paper and its supplementary information files or
from the corresponding author on reasonable request.
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